Disease detection and monitoring company Glympse Bio has raised $22m in series A funding towards developing its in vivo sensing technology. The Cambridge, Massachusetts-based firm is creating technology that can be delivered to the area of diseased tissue in patients, where it can examine the area's biological activity before emitting a signal that can be detected through urine. The company is currently focusing on non-alcoholic steatohepatitis, or NASH, which can lead to cirrhosis of the liver. Another report by the same research firm last month projected that the therapeutics and diagnostics market would grow at a 25 percent annual rate between this year and 2023, driven by the rising prevalence of people with diabetes and obesity. In addition to being able to detect disease at an early stage, this new sensor could also help doctors diagnose liver damage more accurately by detecting changes in blood sugar levels as well as other biomarkers such
Disease detection and monitoring company Glympse Bio has raised $22m in series A funding towards developing its in vivo sensing technology. The Cambridge, Massachusetts-based firm is creating technology that can be delivered to the area of diseased tissue in patients, where it can examine the area's biological activity before emitting a signal that can be detected through urine. The company is currently focusing on non-alcoholic steatohepatitis, or NASH, which can lead to cirrhosis of the liver. In addition to being able to detect disease at an early stage, this new sensor could also help doctors diagnose liver damage more accurately by detecting changes in blood sugar levels as well as other biomarkers such